SG10201610508VA - Methods of detecting diseases or conditions - Google Patents
Methods of detecting diseases or conditionsInfo
- Publication number
- SG10201610508VA SG10201610508VA SG10201610508VA SG10201610508VA SG10201610508VA SG 10201610508V A SG10201610508V A SG 10201610508VA SG 10201610508V A SG10201610508V A SG 10201610508VA SG 10201610508V A SG10201610508V A SG 10201610508VA SG 10201610508V A SG10201610508V A SG 10201610508VA
- Authority
- SG
- Singapore
- Prior art keywords
- conditions
- methods
- detecting diseases
- diseases
- detecting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261660427P | 2012-06-15 | 2012-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201610508VA true SG10201610508VA (en) | 2017-02-27 |
Family
ID=49758768
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408385TA SG11201408385TA (en) | 2012-06-15 | 2013-06-14 | Methods of detecting diseases or conditions |
| SG10201610508VA SG10201610508VA (en) | 2012-06-15 | 2013-06-14 | Methods of detecting diseases or conditions |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408385TA SG11201408385TA (en) | 2012-06-15 | 2013-06-14 | Methods of detecting diseases or conditions |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20150275298A1 (en) |
| EP (1) | EP2861765B1 (en) |
| JP (1) | JP2015522260A (en) |
| KR (1) | KR20150035821A (en) |
| CN (1) | CN104603289A (en) |
| AU (1) | AU2013274002A1 (en) |
| BR (1) | BR112014031365A2 (en) |
| CA (1) | CA2876731A1 (en) |
| EA (1) | EA201590027A1 (en) |
| HK (1) | HK1209793A1 (en) |
| IL (1) | IL236181A0 (en) |
| MX (1) | MX2014015425A (en) |
| SG (2) | SG11201408385TA (en) |
| WO (1) | WO2013188846A1 (en) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014164362A1 (en) | 2013-03-09 | 2014-10-09 | Harry Stylli | Methods of detecting prostate cancer |
| NZ771629A (en) | 2013-03-09 | 2022-12-23 | Harry Stylli | Methods of detecting cancer |
| US20150260631A1 (en) * | 2014-03-17 | 2015-09-17 | Health Diagnostic Laboratory, Inc. | System and method for assessing quanitites or sizes of lipoprotein particles from lipoprotein particle compositions |
| US9662649B2 (en) | 2013-05-06 | 2017-05-30 | Hitachi Chemical Company America, Ltd. | Devices and methods for capturing target molecules |
| BR112016010095A2 (en) | 2013-11-07 | 2017-09-12 | Univ Leland Stanford Junior | free cell nucleic acids for human microbiome analysis and components thereof. |
| WO2015095359A1 (en) * | 2013-12-17 | 2015-06-25 | Harry Stylli | Methods of detecting diseases or conditions |
| EP3161482B1 (en) * | 2014-06-27 | 2020-08-26 | XY Evergreen Technology Company | Method for enriching cns-derived exosomes |
| WO2016004221A1 (en) * | 2014-07-01 | 2016-01-07 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments |
| US10626464B2 (en) | 2014-09-11 | 2020-04-21 | Cell Mdx, Llc | Methods of detecting prostate cancer |
| CN105525033A (en) * | 2014-09-29 | 2016-04-27 | 天津华大基因科技有限公司 | Method and device for detecting microorganisms in blood |
| US10266895B2 (en) | 2014-11-05 | 2019-04-23 | Hitachi Chemical Company Ltd. | Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease |
| WO2016077537A1 (en) * | 2014-11-12 | 2016-05-19 | Hitachi Chemical Co., Ltd. | Method and device for diagnosing organ injury |
| US11242559B2 (en) * | 2015-01-13 | 2022-02-08 | The Chinese University Of Hong Kong | Method of nuclear DNA and mitochondrial DNA analysis |
| CN107530064B (en) | 2015-03-06 | 2021-07-30 | 英国质谱公司 | Improved ionization of gaseous samples |
| CN107667288B (en) | 2015-03-06 | 2022-02-01 | 英国质谱公司 | Spectral analysis of microorganisms |
| CA2978042A1 (en) | 2015-03-06 | 2016-09-15 | Micromass Uk Limited | Tissue analysis by mass spectrometry or ion mobility spectrometry |
| EP3265817B1 (en) | 2015-03-06 | 2020-08-12 | Micromass UK Limited | Rapid evaporative ionisation mass spectrometry ("reims") and desorption electrospray ionisation mass spectrometry ("desi-ms") analysis of swabs and biopsy samples |
| EP3266035B1 (en) | 2015-03-06 | 2023-09-20 | Micromass UK Limited | Collision surface for improved ionisation |
| CN107533032A (en) | 2015-03-06 | 2018-01-02 | 英国质谱公司 | MALDI-MS in situ for directly being mapped from massive texture determines imaging platform |
| WO2016142692A1 (en) | 2015-03-06 | 2016-09-15 | Micromass Uk Limited | Spectrometric analysis |
| GB2556436B (en) | 2015-03-06 | 2022-01-26 | Micromass Ltd | Cell population analysis |
| CA2977906A1 (en) | 2015-03-06 | 2016-09-15 | Micromass Uk Limited | In vivo endoscopic tissue identification tool |
| EP3298169A4 (en) | 2015-05-18 | 2018-10-24 | Karius Inc. | Compositions and methods for enriching populations of nucleic acids |
| CN105037553B (en) * | 2015-08-20 | 2018-04-17 | 内蒙古蒙元生物基因科技有限公司 | A kind of immunoglobulin that can detect cancer |
| CN106467926A (en) * | 2015-08-20 | 2017-03-01 | 北京京爱康科技有限公司 | A kind of method of phenotype genes in positioning desired phenotype cancerous cell |
| JP6624704B2 (en) | 2015-08-31 | 2019-12-25 | 日立化成株式会社 | Molecular methods for assessing urothelial disease |
| CN105132575B (en) * | 2015-09-28 | 2020-03-27 | 固安博健生物技术有限公司 | Molecular marker for osteoporosis and application thereof |
| GB201517195D0 (en) | 2015-09-29 | 2015-11-11 | Micromass Ltd | Capacitively coupled reims technique and optically transparent counter electrode |
| CN105132429A (en) * | 2015-10-10 | 2015-12-09 | 华东理工大学 | SiRNA targeted to human KPNB1 genes and application thereof |
| CN107151697B (en) * | 2016-03-04 | 2021-05-07 | 厦门大学 | Method and kit for predicting the response of chronic hepatitis B patients to IFN alpha therapy |
| EP4198146A3 (en) | 2016-03-25 | 2023-08-23 | Karius, Inc. | Methods using synthetic nucleic acid spike-ins |
| WO2017178833A1 (en) | 2016-04-14 | 2017-10-19 | Micromass Uk Limited | Spectrometric analysis of plants |
| TWI780046B (en) * | 2016-05-10 | 2022-10-11 | 國立大學法人東京醫科齒科大學 | Expression suppressors of pro-inflammatory factors, screening method of effective ingredients thereof, expression cassettes usuful to the method, diagnostic agents and disgnostic methods |
| CN106018372B (en) * | 2016-07-19 | 2018-06-05 | 济南大学 | Difunctional combined probe builds fluorescence/colorimetric bimodulus MiRNA sensors |
| JP7195002B2 (en) | 2016-09-02 | 2022-12-23 | ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム | Recovery probe and method for its use |
| CN106434982B (en) * | 2016-11-24 | 2018-08-14 | 汕头大学医学院第一附属医院 | The relevant molecular marked compound of cerebral arterial thrombosis and its application |
| CN106636366A (en) * | 2016-11-25 | 2017-05-10 | 苏州首度基因科技有限责任公司 | Gene detection kit for prognosing gastric cancer metastasis and use method of gene detection kit |
| CA3059370C (en) | 2017-04-12 | 2022-05-10 | Karius, Inc. | Methods for concurrent analysis of dna and rna in mixed samples |
| CN110462064A (en) * | 2017-04-18 | 2019-11-15 | 深圳华大生命科学研究院 | The method and its application of microorganism detection are carried out based on excretion body nucleic acid |
| CN107475366B (en) * | 2017-07-03 | 2020-04-28 | 博尔诚（北京）科技有限公司 | Composition for detecting diseases and kit and application thereof |
| WO2019018545A1 (en) | 2017-07-18 | 2019-01-24 | The Research Foundation For The State University Of New York | Biomarkers for intracranial aneurysm |
| CN107563069A (en) * | 2017-09-06 | 2018-01-09 | 国电联合动力技术有限公司 | A kind of wind power generating set intelligent fault diagnosis method |
| SG11202004568UA (en) | 2017-11-27 | 2020-06-29 | Univ Texas | Minimally invasive collection probe and methods for the use thereof |
| CN108300716B (en) * | 2018-01-05 | 2020-06-30 | 武汉康测科技有限公司 | Linker element, application thereof and method for constructing targeted sequencing library based on asymmetric multiplex PCR |
| CN108384840A (en) * | 2018-01-24 | 2018-08-10 | 安徽微分基因科技有限公司 | A kind of buccal swab is without extraction TP53SNP methods of genotyping |
| EP3812759A4 (en) * | 2018-06-20 | 2022-07-27 | Tosoh Corporation | Method for separating antibody, and method for testing on disease |
| WO2020051530A1 (en) * | 2018-09-07 | 2020-03-12 | Juneau Biosciences, L.L.C. | Methods of using genetic markers associated with endometriosis |
| KR20200048740A (en) | 2018-10-30 | 2020-05-08 | (주)아모레퍼시픽 | A composition for skin barrier function comprising DNAJA1 promoting materials and a method for screening DNAJA1 promoting materials |
| CN109371123B (en) * | 2018-12-24 | 2022-06-17 | 中国医学科学院北京协和医院 | Probe set and kit for detecting pathogenic gene of autoinflammatory disease |
| CN113853443A (en) * | 2019-03-08 | 2021-12-28 | 株式会社Neogentc | Marker for predicting tumor reactivity of lymphocytes and use thereof |
| CN113646635A (en) * | 2019-04-04 | 2021-11-12 | 马格雷股份有限公司 | Method for generating a circulating analyte profile and apparatus for performing the method |
| BR122021009560B1 (en) * | 2019-08-16 | 2023-11-28 | The Chinese University Of Hong Kong | METHOD FOR DETECTING A MODIFICATION OF A NUCLEOTIDE IN A NUCLEIC ACID MOLECULE |
| WO2021041931A1 (en) * | 2019-08-28 | 2021-03-04 | The Regents Of The University Of California | Methods of producing dna methylation profiles |
| KR102376945B1 (en) * | 2019-12-19 | 2022-03-21 | 상지대학교산학협력단 | Parkinson's disease pharmaceutical composition and its therapeutic agent |
| EP4121553A1 (en) * | 2020-03-18 | 2023-01-25 | Molecular Stethoscope, Inc. | Systems and methods of detecting a risk of alzheimer's disease using a circulating-free mrna profiling assay |
| CN113913424B (en) * | 2020-07-09 | 2023-08-08 | 四川大学华西医院 | Adeno-associated virus and application thereof in preparation of medicines for treating cocaine addiction |
| KR102400464B1 (en) * | 2020-07-28 | 2022-05-19 | 부산대학교 산학협력단 | Biomarker composition for detecting cancer stem cell |
| CN111679018B (en) * | 2020-08-14 | 2020-11-20 | 宝枫生物科技（北京）有限公司 | Biomarkers for diagnosing cognitive disorders and uses thereof |
| CN112415198B (en) * | 2020-11-20 | 2022-11-11 | 四川大学华西医院 | Application of GP1BB detection reagent in preparation of lung cancer screening kit |
| CN112843222B (en) * | 2021-01-21 | 2023-01-31 | 暨南大学 | Application of ANKRD22 protein in preparing product for treating or delaying autoimmune diseases |
| CN113075399B (en) * | 2021-03-29 | 2021-09-21 | 广州市妇女儿童医疗中心 | Application of anti-single-chain DNA antibody as diagnosis marker of Hirschmannin |
| US20230111049A1 (en) * | 2021-10-08 | 2023-04-13 | Waters Technologies Corporation | Sample preparation for lc-ms based sequence mapping of nucleic acids |
| WO2023150676A2 (en) * | 2022-02-03 | 2023-08-10 | The Brigham And Women's Hospital, Inc. | Companion diagnostic for human ceacam1 directed therapeutic agents |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2702148C (en) | 1999-01-06 | 2014-03-04 | Genenews Inc. | Method of profiling gene expression in a human subject having an infectious disease |
| GB0104690D0 (en) | 2001-02-26 | 2001-04-11 | Cytogenetic Dna Services Ltd | Diagnostic test |
| FR2824144B1 (en) * | 2001-04-30 | 2004-09-17 | Metagenex S A R L | METHOD OF PRENATAL DIAGNOSIS ON FETAL CELLS ISOLATED FROM MATERNAL BLOOD |
| EP1389306A2 (en) | 2001-05-09 | 2004-02-18 | BioVisioN AG | Method for detecting progredient chronic dementia, and corresponding peptides and detection reagents |
| JP2006523082A (en) * | 2002-03-01 | 2006-10-12 | ラブジェン， インコーポレイテッド | Rapid analysis of mutations in the genome |
| EP1520172A1 (en) | 2002-07-05 | 2005-04-06 | EVOTEC Neurosciences GmbH | Diagnostic and therapeutic use of tb2 gene and protein for neurodegenerative diseases |
| FR2844279A1 (en) | 2002-09-06 | 2004-03-12 | Inst Nat Sante Rech Med | MEANS FOR DETECTING NEURODEGENERATIVE PROCESSES AND THEIR APPLICATIONS |
| GB0225360D0 (en) | 2002-10-31 | 2002-12-11 | Univ London | Genetic markers |
| WO2004070388A1 (en) | 2003-02-04 | 2004-08-19 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases |
| US20080107600A1 (en) | 2003-02-13 | 2008-05-08 | Taiichi Katayama | Gene Marker And Composition For Diagnosis And Treatment Of Neurological Disorders And Diseases And Use Of The Same |
| CA2539535A1 (en) | 2003-10-03 | 2005-04-14 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Use of cripto-1 as a biomarker for neurodegenerative disease and method of inhibiting progression thereof |
| US20060094064A1 (en) | 2003-11-19 | 2006-05-04 | Sandip Ray | Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids |
| WO2005052592A2 (en) | 2003-11-19 | 2005-06-09 | Satoris, Inc. | Methods for diagnosis, stratification, and monitoring of alzheimer’s disease |
| EP1685410A1 (en) | 2003-11-19 | 2006-08-02 | EVOTEC Neurosciences GmbH | Diagnostic and therapeutic use of the human sgpl1 gene and protein for neurodegenerative diseases |
| WO2005072340A2 (en) | 2004-01-27 | 2005-08-11 | Compugen Ltd. | Novel polynucleotides encoding polypeptides and methods using same |
| US20080269103A1 (en) | 2004-02-04 | 2008-10-30 | Heinz Von Der Kammer | Diagnostic and Therapeutic Use of the Kcne4 Gene and Protein for Alzheimer's Disease |
| US20080051334A1 (en) | 2004-04-16 | 2008-02-28 | Evotec Neurosciences Gmbh | Diagnostic and Therapeutic Use of Kcnc1 for Neurodegenerative Diseases |
| EP2369350B1 (en) | 2004-04-20 | 2014-08-20 | SphingoTec GmbH | Use of precursors of tachykinins and/or their fragments in medical diagnostic |
| WO2005108582A1 (en) | 2004-05-07 | 2005-11-17 | Garvan Institute Of Medical Research | DETECTING DISEASE ASSOCIATION WITH ABERRANT GLYCOGEN SYNTHASE KINASE 3β EXPRESSION |
| WO2005108999A2 (en) | 2004-05-10 | 2005-11-17 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease |
| JP4976282B2 (en) | 2004-05-13 | 2012-07-18 | ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー | Use of enkephalin precursors and / or fragments thereof in medical diagnosis |
| BRPI0511435A (en) | 2004-05-19 | 2007-12-26 | Uinv Kobenhavns | adam12, a new marker for abnormal cell function |
| CN101137903A (en) | 2004-07-19 | 2008-03-05 | 罗彻斯特大学 | Biomarkers of neurodegenerative disease |
| DK2299275T3 (en) | 2004-07-30 | 2018-05-07 | Adeza Biomedical Corp | Classification of oncofetal fetronectin level for pregnancy-related indications |
| US20070087376A1 (en) | 2004-08-30 | 2007-04-19 | Potashkin Judith A | Splice variants of pre-mRNA transcripts as biomarkers in idiopathic neurodegenerative diseases |
| US7595159B2 (en) | 2004-11-03 | 2009-09-29 | The Brigham And Women's Hospital, Inc. | Prediction of Parkinson's disease using gene expression levels of peripheral blood samples |
| WO2006048778A1 (en) | 2004-11-08 | 2006-05-11 | King's College London | Markers of predisposition to addictive states |
| US20060115854A1 (en) | 2004-12-01 | 2006-06-01 | Power3 Medical Products, Inc. | Acetyl-LDL receptor related proteins and peptides as a biomarker for neurodegenerative disease |
| US20060115855A1 (en) | 2004-12-01 | 2006-06-01 | Power3 Medical Products, Inc. | FK506-binding protein 7 related protein as a biomarker for neurodegenerative disease |
| GB0426859D0 (en) | 2004-12-07 | 2005-01-12 | Proteome Sciences Plc | Diagnosis of neurodegenerative disorders |
| CA2590781A1 (en) | 2004-12-07 | 2006-06-15 | Electrophoretics Limited | Diagnosis of neurodegenerative diseases |
| US7572592B2 (en) | 2005-01-31 | 2009-08-11 | Glycominds Ltd | Method for diagnosing multiple sclerosis |
| US20070141625A1 (en) | 2005-02-03 | 2007-06-21 | Santos Jose H | Method for assessing risk of and predisposition to development of a pathology related to the presence of anti-epcr autoantibodies |
| US7645576B2 (en) * | 2005-03-18 | 2010-01-12 | The Chinese University Of Hong Kong | Method for the detection of chromosomal aneuploidies |
| ATE468537T1 (en) | 2005-04-06 | 2010-06-15 | Verstappen Leopold | NEURODEGENERATIVE MARKERS FOR DEPRESSION. |
| GB0512401D0 (en) | 2005-06-17 | 2005-07-27 | Randox Lab Ltd | Method |
| GB2428240A (en) | 2005-07-14 | 2007-01-24 | Univ Gen Ve | Diagnostic method for brain damage-related disorders |
| US20070148661A1 (en) | 2005-07-19 | 2007-06-28 | Duke University | LSAMP Gene Associated With Cardiovascular Disease |
| CN100410663C (en) * | 2005-09-11 | 2008-08-13 | 翁炳焕 | Proteomics ante partum diagnosis process |
| US20080038761A1 (en) | 2006-01-30 | 2008-02-14 | Invitrogen Corporation | Compositions and methods for detecting and quantifying toxic substances in disease states |
| KR20080104350A (en) | 2006-02-28 | 2008-12-02 | 페노미넘 디스커버리스 인코포레이티드 | Methods for the diagnosis of dementia and other neurological disorders |
| EP1847615A1 (en) | 2006-04-18 | 2007-10-24 | Genoscreen | Expression and polymorphism of the ornithine transcarbamylase (OTC) gene as markers for diagnosing Alzheimer's disease |
| US20090305265A1 (en) | 2006-04-27 | 2009-12-10 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
| EP3059594A1 (en) | 2006-05-01 | 2016-08-24 | Critical Care Diagnostics, Inc. | Prognosis of cardiovascular disease |
| WO2007131345A1 (en) | 2006-05-12 | 2007-11-22 | The Hospital For Sick Children | Genetic risk factor in sod1 and sfrs15 in renal disease, diabetic cataract, cardiovascular disease and longevity |
| EP2548578B1 (en) | 2006-05-17 | 2014-08-20 | The Ludwig Institute for Cancer Research | Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases |
| US20100009352A1 (en) | 2006-05-24 | 2010-01-14 | Gough Albert H | Method for Modeling a Disease |
| DE102006027818A1 (en) | 2006-06-16 | 2007-12-20 | B.R.A.H.M.S. Aktiengesellschaft | In vitro multiparameter determination method for the diagnosis and early diagnosis of neurodegenerative diseases |
| WO2008003826A1 (en) | 2006-07-07 | 2008-01-10 | Oy Jurilab Ltd | Novel genes and markers in essential arterial hypertension |
| KR100856375B1 (en) | 2006-07-18 | 2008-09-04 | 김현기 | Marker for diagnosing Neurodegenerative diseases |
| US7851172B2 (en) | 2006-07-25 | 2010-12-14 | University Of Kentucky Research Foundation | Biomarkers of mild cognitive impairment and alzheimer's disease |
| WO2008014516A2 (en) | 2006-07-28 | 2008-01-31 | Living Microsystems, Inc. | Selection of cells using biomarkers |
| US20080152589A1 (en) | 2006-09-08 | 2008-06-26 | Peter Schofield | Diagnostics and Therapeutics of Neurological Disease |
| US20090318354A1 (en) | 2006-09-26 | 2009-12-24 | Proteosys Ag | Use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1) |
| US20100081136A1 (en) | 2006-10-16 | 2010-04-01 | Stefan Golz | Crtac as a biomarker, therapeutic and diagnostic target |
| EP2102357B1 (en) | 2006-10-16 | 2013-11-27 | Bayer Intellectual Property GmbH | Ltbp2 as a biomarker, therapeutic and diagnostic target |
| WO2008046510A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Healthcare Ag | Fn1 as a biomarker, therapeutic and diagnostic target |
| WO2008046512A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Schering Pharma Aktiengesellschaft | Prss23 as a biomarker, therapeutic and diagnostic target |
| WO2008063369A2 (en) | 2006-11-01 | 2008-05-29 | George Mason Intellectual Properties, Inc. | Biomarkers for neurological conditions |
| WO2008068024A2 (en) | 2006-12-06 | 2008-06-12 | Universität Zürich | Means and methods for isolating and determining novel targets for the treatment of neurodegenerative, neurological or neuropsychiatric disorders and compositions comprising the same |
| US8815519B2 (en) | 2006-12-22 | 2014-08-26 | Hvidovre Hospital | Method for predicting cancer and other diseases |
| WO2008085024A1 (en) | 2007-01-12 | 2008-07-17 | Erasmus University Medical Center Rotterdam | Identification and detection of peptides relating to specific disorders |
| WO2008095261A1 (en) | 2007-02-08 | 2008-08-14 | Powmri Limited | Method of diagnosing a neurodegenerative disease |
| WO2008100596A2 (en) | 2007-02-15 | 2008-08-21 | Burnham Institute For Medical Research | Biomarkers of neurodegenerative disease |
| WO2008102380A1 (en) | 2007-02-21 | 2008-08-28 | Decode Genetics Ehf | Genetic susceptibility variants associated with cardiovascular disease |
| WO2008118813A2 (en) | 2007-03-26 | 2008-10-02 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Schizophrenia-related isoform of kcnh2 and development of antipsychotic drugs |
| JP5555846B2 (en) | 2007-03-30 | 2014-07-23 | 国立大学法人山口大学 | Prognosis determination method for acute central nervous system disorder |
| PL390236A1 (en) | 2007-04-12 | 2010-07-05 | Apitope International Nvapitope International Nv | Biomarkers of multiple sclerosis |
| GB0708075D0 (en) | 2007-04-26 | 2007-06-06 | Univ Nottingham | Nethods |
| AU2008247649A1 (en) | 2007-05-01 | 2008-11-13 | University Of Miami | Transcriptomic biomarkers for individual risk assessment in new onset heart failure |
| ITRM20070351A1 (en) | 2007-06-22 | 2008-12-23 | Istituto Naz Per Le Malattie I | GENE CODIFYING AMBER PROTEIN 1 HAVING REGULATORY ACTIVITY OF THE SELF-FAILURE AND DEVELOPMENT OF THE CENTRAL NERVOUS SYSTEM |
| WO2009000520A1 (en) | 2007-06-25 | 2008-12-31 | Universität Duisburg-Essen | Screening-method for polymorphic markers in htra1 gene in neurodegenerative disorders |
| WO2009003142A1 (en) | 2007-06-27 | 2008-12-31 | The Board Of Trustees Of The Leland, Stanford Junior University | Beta2-microglobulin and c reactive protein (crp) as biomarkers for peripheral artery disease |
| FR2918329B1 (en) | 2007-07-06 | 2009-10-02 | Renault Sas | COOLING ECOPE FOR MOTOR VEHICLE |
| US8187830B2 (en) | 2007-07-17 | 2012-05-29 | Metabolon, Inc. | Method for determining insulin sensitivity with biomarkers |
| US20090275046A1 (en) | 2007-08-29 | 2009-11-05 | Power3 Medical Products, Inc. | Complement factor H protein as a biomarker of Parkinson's disease |
| US9086425B2 (en) | 2007-08-29 | 2015-07-21 | The Cleveland Clinic Foundation | Carbamylated proteins and risk of cardiovascular disease |
| GB0717637D0 (en) | 2007-09-10 | 2007-10-17 | Univ Leiden | Future cardiac event biomarkers |
| CA2703165A1 (en) | 2007-10-22 | 2009-04-30 | The Regents Of The University Of California | Biomarkers for prenatal diagnosis of congenital cytomegalovirus |
| FI20070795A0 (en) | 2007-10-24 | 2007-10-24 | Faron Pharmaceuticals Oy | A new biomarker for monitoring disease development and assessing the effectiveness of therapies |
| WO2009058168A1 (en) | 2007-11-04 | 2009-05-07 | Prediction Sciences Llc | Cellular fibronectin as a diagnostic marker in cardiovascular disease and methods of use thereof |
| US20100255485A1 (en) | 2007-11-28 | 2010-10-07 | Pico Caroni | Biomarkers for the onset of neurodegenerative diseases |
| US8506933B2 (en) | 2007-11-30 | 2013-08-13 | Msdx, Inc. | Methods of detecting a neurological condition via analysis of circulating phagocytes |
| WO2009074331A2 (en) | 2007-12-11 | 2009-06-18 | Julius-Maximilians-Universität Würzburg | Early and differential diagnosis test for alzheimer's disease |
| WO2009075566A1 (en) | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Biomarkers for cardiovascular disease |
| EP3779444A1 (en) * | 2008-01-18 | 2021-02-17 | President and Fellows of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| JP2011510308A (en) | 2008-01-23 | 2011-03-31 | リグスホスピタル | Classification of individuals suffering from cardiovascular disease based on survival prognosis found by measuring the level of biomarker YKL-40 |
| US20090299155A1 (en) | 2008-01-30 | 2009-12-03 | Dexcom, Inc. | Continuous cardiac marker sensor system |
| CN101983337A (en) | 2008-02-04 | 2011-03-02 | 班扬生物标记公司 | Process to diagnose or treat brain injury |
| CA2646040A1 (en) | 2008-03-22 | 2009-09-22 | David V. Pow | Detection of a biomarker of aberrant cells of neuroectodermal origin in a body fluid |
| GB0809069D0 (en) | 2008-05-19 | 2008-06-25 | Univ Leuven Kath | Gene signatures |
| EP2107377A1 (en) | 2008-04-04 | 2009-10-07 | BRAHMS Aktiengesellschaft | Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events |
| US8030097B2 (en) | 2008-04-30 | 2011-10-04 | Versitech Limited and R & C Biogenius Limited | Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks |
| WO2010005750A2 (en) | 2008-06-16 | 2010-01-14 | The Regents Of The University Of California | Potential prognostic markers and therapeutic targets for neurological disorders |
| US20100167937A1 (en) | 2008-07-08 | 2010-07-01 | Power3 Medical Products, Inc. | Multiple forms of Alzheimer's disease based on differences in concentrations of protein biomarkers in blood serum |
| US20110177509A1 (en) | 2008-07-23 | 2011-07-21 | The Washington University | Risk factors and a therapeutic target for neurodegenerative disorders |
| AU2009282117B2 (en) | 2008-08-11 | 2016-05-12 | Banyan Biomarkers, Inc. | Biomarker detection process and assay of neurological condition |
| GB0818650D0 (en) | 2008-10-10 | 2008-11-19 | Uni I Oslo | Methods |
| US20100124756A1 (en) | 2008-10-10 | 2010-05-20 | Sandip Ray | Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids |
| JP2012508028A (en) | 2008-11-11 | 2012-04-05 | エンテロス・インコーポレーテッド | Biomarkers for assessing atherosclerotic potential |
| US20120094295A1 (en) | 2008-11-21 | 2012-04-19 | The Johns Hopkins University | Neurodegenerative disease diagnostic compositions and methods of use |
| IT1392551B1 (en) | 2008-11-25 | 2012-03-09 | Bioindustry Park Del Canavese S P A | BIOMARCERS FOR DIAGNOSIS AND TO DETECT THE PROGRESSION OF NEURODEGENERATIVE DISEASES, IN PARTICULAR OF AMIOTROPHIC LATERAL SCLEROSIS |
| NZ628281A (en) | 2008-12-09 | 2016-05-27 | Stephanie Fryar Williams | Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders |
| US8563242B2 (en) * | 2009-08-11 | 2013-10-22 | The Chinese University Of Hong Kong | Method for detecting chromosomal aneuploidy |
| CN103119179A (en) * | 2010-07-23 | 2013-05-22 | 哈佛大学校长及研究员协会 | Methods for detecting signatures of disease or conditions in bodily fluids |
| EP2596353A4 (en) * | 2010-07-23 | 2014-01-15 | Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
-
2013
- 2013-06-14 CA CA2876731A patent/CA2876731A1/en not_active Abandoned
- 2013-06-14 BR BR112014031365A patent/BR112014031365A2/en not_active IP Right Cessation
- 2013-06-14 EP EP13803548.0A patent/EP2861765B1/en active Active
- 2013-06-14 CN CN201380039509.0A patent/CN104603289A/en active Pending
- 2013-06-14 AU AU2013274002A patent/AU2013274002A1/en not_active Abandoned
- 2013-06-14 SG SG11201408385TA patent/SG11201408385TA/en unknown
- 2013-06-14 EA EA201590027A patent/EA201590027A1/en unknown
- 2013-06-14 US US14/407,850 patent/US20150275298A1/en not_active Abandoned
- 2013-06-14 WO PCT/US2013/046020 patent/WO2013188846A1/en active Application Filing
- 2013-06-14 KR KR20147037128A patent/KR20150035821A/en not_active Application Discontinuation
- 2013-06-14 US US13/918,663 patent/US20140179805A1/en not_active Abandoned
- 2013-06-14 JP JP2015517468A patent/JP2015522260A/en active Pending
- 2013-06-14 SG SG10201610508VA patent/SG10201610508VA/en unknown
- 2013-06-14 MX MX2014015425A patent/MX2014015425A/en unknown
-
2014
- 2014-12-11 IL IL236181A patent/IL236181A0/en unknown
-
2015
- 2015-10-22 HK HK15110373.9A patent/HK1209793A1/en not_active IP Right Cessation
-
2018
- 2018-02-12 US US15/894,388 patent/US20180245158A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150035821A (en) | 2015-04-07 |
| JP2015522260A (en) | 2015-08-06 |
| IL236181A0 (en) | 2015-01-29 |
| CA2876731A1 (en) | 2013-12-19 |
| EA201590027A1 (en) | 2015-05-29 |
| SG11201408385TA (en) | 2015-01-29 |
| MX2014015425A (en) | 2015-07-14 |
| AU2013274002A1 (en) | 2015-02-05 |
| US20140179805A1 (en) | 2014-06-26 |
| WO2013188846A1 (en) | 2013-12-19 |
| EP2861765A1 (en) | 2015-04-22 |
| BR112014031365A2 (en) | 2017-06-27 |
| CN104603289A (en) | 2015-05-06 |
| HK1209793A1 (en) | 2016-04-08 |
| US20150275298A1 (en) | 2015-10-01 |
| US20180245158A1 (en) | 2018-08-30 |
| EP2861765B1 (en) | 2019-01-23 |
| EP2861765A4 (en) | 2016-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1209793A1 (en) | Methods of detecting diseases or conditions | |
| HK1222466A1 (en) | Analysis of genetic variants | |
| IL245794A0 (en) | Methods of detecting plasmodium infection | |
| HK1199743A1 (en) | Detection of nucleic acids | |
| EP2852687A4 (en) | Methods of sample preparation | |
| EP2596117A4 (en) | Methods of detecting kidney-associated diseases or conditions | |
| EP2834627A4 (en) | Calibration of wear detection system | |
| EP2817315A4 (en) | Selective detection of thiols | |
| EP2866854A4 (en) | Methods of using polymers | |
| ZA201406082B (en) | Use of ccr3-inhibitors | |
| EP2825671A4 (en) | Early detection of tuberculosis treatment response | |
| EP2971155A4 (en) | Ligation-based detection of genetic variants | |
| EP2800747A4 (en) | Polymorphs of perampanel | |
| GB201220155D0 (en) | Method of manufacture | |
| IL237862A0 (en) | Methods of reducing scalant formation | |
| GB201215942D0 (en) | Method of treatent | |
| EP2742352A4 (en) | Detection of sex steroids | |
| EP2836518A4 (en) | Methods of detecting glycosaminoglycans | |
| GB201210756D0 (en) | Analysis of small RNA | |
| GB201403183D0 (en) | Detection of neurodegenerative disease | |
| ZA201503833B (en) | Method of hemoglobin-f determination | |
| GB201221046D0 (en) | Method of diagnosis | |
| IL233446A0 (en) | Polymorphs of perampanel | |
| GB201212279D0 (en) | Method of construction | |
| GB201221118D0 (en) | Methods of treatment |